Supplementary material

The 1,3,5-triazine derivatives as innovative chemical family of 5-HT$_6$ serotonin receptor agents with therapeutic perspectives for cognitive impairment

Gniewomir Latacz, Annamaria Lubelska, Magdalena Jastrzębska-Więsek, Anna Partyka, Małgorzata Anna Marć, Grzegorz Satała, Daria Wilczyńska, Magdalena Kotańska, Małgorzata Więcek, Katarzyna Kamińska, Anna Wesołowska, Katarzyna Kieć-Kononowicz, Jadwiga Handzlik

Table of contents:

1. MS spectra and MS ion fragment analyses of compound 1 and its metabolites.

A



B



Figure S1. MS spectrum of compound **1** (A) and its MS ion fragment analysis (B).



Figure S2. MS spectrum of compound's **1** metabolite M1 (A) and its MS ion fragment analysis (B).



Figure S3. MS spectrum of compound's **1** metabolite M2 (A) and its MS ion fragment analysis (B).

2. MS spectra and MS ion fragment analyses of compound 2 and its metabolites.

A



B



Figure S4. MS spectrum of compound **2** (A) and its MS ion fragment analysis (B).

A



B



Figure S5. MS spectrum of compound's **2** metabolite M1 (A) and its MS ion fragment analysis (B).

A



B



Figure S6. MS spectrum of compound's **2** metabolite M2 (A) and its MS ion fragment analysis (B)

3. MS spectra and MS ion fragment analyses of compound 3 and its metabolites.

A



B



Figure S7. MS spectrum of compound **3** (A) and its MS ion fragment analysis (B).

A



B



Figure S8. MS spectrum of compound's **3** metabolite M1 (A) and its MS ion fragment analysis (B).

A



B



Figure S9 MS spectrum of compound's **3** metabolite M2 (A) and its MS ion fragment analysis (B).

A



B



Figure S10 MS spectrum of compound's **3** metabolite M3 (A) and its MS ion fragment analysis (B).

4. MS spectra and MS ion fragment analyses of compound 4 and its metabolites.

A



B



Figure S11. MS spectrum of compound **4** (A) and its MS ion fragment analysis (B).

A



B



Figure S12 MS spectrum of compound's **4** metabolite M1 (A) and its MS ion fragment analysis (B).



Figure S13 MS spectrum of compound's **4** metabolite M2 (A) and its MS ion fragment analysis (B).



Figure S14 MS spectrum of compound's **4** metabolite M3 (A) and its MS ion fragment analysis (B).



Figure S15 MS spectrum of compound's **4** metabolite M4 (A) and its MS ion fragment analysis (B).



Figure S16 UPLC spectra of the reaction mixture after 120 min incubation of reference drug verapamil with HLMs.